Print PDF
Landmon Provides Insights on Generics Challenge of AstraZeneca's Crestor Patents to Pharmawire
May 10, 2010

In an article focusing on generic companies'  attempts to invalidate AstraZeneca’s Crestor patents, Axinn partner Chad Landmon discussed the likelihood of invalidating the patents based on claims of inequitable conduct. In the article published by Pharmawire on May 10, 2010, the authors wrote that attorneys representing Teva, Apotex, Aurobindo Pharma, Mylan, Par Pharmaceuticals, Sandoz, Cobalt and Glenmark claimed that the original innovators at Shionigi & Co. engaged in inequitable conduct when applying for Crestor’s patents. The attorneys further argued that the patents were improperly reissued and were obvious. AstraZeneca licensed the rights to Crestor from Shinogi in April 1998. Landmon discussed the inequitable conduct defense with Pharmawire.  He noted that a loss of the case would have a greater impact on AstraZeneca than on the generic manufacturers. “The real company with a lot to lose is AstraZeneca,” he said. Landmon noted that generic manufacturers tend to engage in a lot of patent litigation and  "just losing this one lawsuit would hardly impact them.”

The article appeared on Pharmawire on May 10, 2010. 

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.